

1.1 Table: Cumulative number of participants by type of care provider

Date	In cohort centers	In affiliated hospitals	In private practices	TOTAL
2008	13389	510	1733	15632
2009	13783	589	1877	16249
2010	14114	656	2001	16771
2011	14442	776	2117	17335
2012	14772	826	2222	17820
2013	15134	899	2319	18352
2014	15470	964	2416	18850
2015	15762	1041	2488	19291
2016	16060	1110	2573	19743
2017	16325	1171	2645	20141
2018	16576	1217	2707	20500
2019	16797	1275	2780	20852
2020	16918	1344	2833	21095
2021	17080	1421	2878	21379
2022	17243	1471	2905	21619
2023	17415	1517	2934	21866
2024	17604	1572	2959	22135

1.2 Table: Cumulative number of participants, by recruitment center

Date	BE	BS	GE	SG	TI	VD	ZH	Total
2008	1987	1484	2466	913	488	2419	5875	15632
2009	2078	1560	2527	945	504	2514	6121	16249
2010	2149	1629	2567	972	515	2590	6349	16771
2011	2221	1735	2644	1006	525	2663	6541	17335
2012	2287	1787	2722	1048	534	2739	6703	17820
2013	2367	1855	2790	1076	557	2840	6867	18352
2014	2431	1920	2853	1105	568	2936	7037	18850
2015	2499	1984	2901	1134	580	3019	7174	19291
2016	2549	2058	2950	1159	600	3095	7332	19743
2017	2600	2116	3002	1194	615	3174	7440	20141
2018	2647	2169	3047	1216	626	3238	7557	20500
2019	2696	2214	3079	1245	636	3307	7675	20852
2020	2728	2254	3108	1265	642	3357	7741	21095
2021	2762	2285	3127	1286	649	3414	7856	21379
2022	2779	2326	3136	1310	665	3468	7935	21619
2023	2798	2369	3151	1334	682	3522	8010	21866
2024	2827	2416	3188	1353	693	3585	8073	22135

1.3 Table: Recruitment by center and year

Date	BE	BS	GE	SG	TI	VD	ZH	Total
2008	107	51	68	27	20	81	232	586
2009	91	76	61	32	16	95	246	617
2010	71	69	40	27	11	76	228	522
2011	72	106	77	34	10	73	192	564
2012	66	52	78	42	9	76	162	485
2013	80	68	68	28	23	101	164	532
2014	64	65	63	29	11	96	170	498
2015	68	64	48	29	12	83	137	441
2016	50	74	49	25	20	76	158	452
2017	51	58	52	35	15	79	108	398
2018	47	53	45	22	11	64	117	359
2019	49	45	32	29	10	69	118	352
2020	31	40	27	19	6	51	65	239
2021	34	31	20	21	7	57	115	285
2022	18	41	12	26	16	57	81	251
2023	19	43	15	25	17	55	76	250
2024	29	47	37	20	11	63	63	270

1.4 Table: Participants under follow-up (i.e. seen in the respective year), by center

Date	BE	BS	GE	SG	TI	VD	ZH	Total
2012	1178	958	1208	553	304	1268	3204	8660
2013	1220	1020	1229	563	318	1347	3275	8958
2014	1242	1047	1256	576	320	1414	3355	9199
2015	1294	1090	1266	592	322	1451	3405	9412
2016	1315	1135	1271	604	327	1477	3450	9565
2017	1303	1161	1263	622	336	1514	3458	9642
2018	1322	1167	1237	632	336	1524	3496	9706
2019	1353	1190	1234	651	336	1552	3490	9790
2020	1341	1191	1187	644	324	1559	3388	9621
2021	1336	1186	1141	658	327	1556	3420	9605
2022	1296	1176	1102	653	326	1571	3374	9483
2023	1287	1157	1005	662	340	1555	3329	9318
2024	1256	1157	1047	659	340	1563	3267	9280

1.5 Table: Cumulative number of participants by sex and transmission category, by most recent center

	BE	BS	GE	SG	TI	VD	ZH	total
Sex: Male	1636	1457	1611	787	455	1926	8291	16163
Sex: Female	764	635	735	339	190	985	2323	5971
Transmission category: Homosexual	785	795	896	320	209	1016	4873	8894
Transmission category: Heterosexual	996	799	962	460	247	1324	2470	7258
Transmission category: Injection drug use	283	228	217	181	104	302	2029	3344
Transmission category: Inj. drug or sexual	174	108	113	66	57	119	886	1523
Transmission category: Other/unknown	162	163	158	99	28	150	356	1116

1.6 Table: Patients recruited in 2024, by age, sex, ethnicity, transmission category

	BE	BS	GE	SG	TI	VD	ZH	total
Age, Median (IQR)	44 (38-54)	39.5 (32-50)	43 (35-48)	40.5 (34-46)	52 (38-62)	41 (31-50)	35 (30-42)	40 (32-49)
Age: 18 to 24	1	1	1	0	0	8	6	17
Age: 25 to 44	15	27	22	14	3	31	44	156
Age: 45 to 64	12	17	12	6	7	20	10	84
Age: >65	1	1	2	0	1	4	4	13
Ethnicity: White	21	31	17	14	11	27	48	169
Ethnicity: Black	3	10	11	3	0	25	4	56
Ethnicity: Hispanic	4	2	7	2	0	9	6	30
Ethnicity: Asian	1	0	1	1	0	2	5	10
Sex: Male	17	36	25	14	10	37	59	198
Sex: Female*	12	9	12	6	1	26	5	71
Transmission category: Homosexual	13	27	15	8	5	23	40	131
Transmission category: Hetersexual	15	13	15	7	5	28	15	98
Transmission category: Injection drug use	0	0	0	1	1	0	1	3
Transmission category: Inj. drug or sexual	1	0	0	0	0	0	0	1
Transmission category: Other/unknown	0	6	7	4	0	12	8	37

**One person reported "non-binary" (category was newly introduced), but excluded for identifiability reasons*

1.7 Table: Participants under follow-up in 2024 by age, sex, ethnicity, transmission category

	BE	BS	GE	SG	TI	VD	ZH	total
Age, Median (IQR)	56 (46-62)	55 (47-62)	57 (46-63)	55 (46-62)	58 (46-63)	54 (46-62)	55 (46-62)	55 (46-62)
Age: 18 to 24	4	2	6	6	1	12	23	54
Age: 25 to 44	232	251	182	155	50	368	691	1929
Age: 45 to 64	800	688	627	379	218	910	2000	5622
Age: >65	218	212	232	118	71	273	551	1675
Ethnicity: White	901	873	664	532	312	1022	2678	6982
Ethnicity: Black	235	160	270	79	9	419	224	1396
Ethnicity: Asian	44	43	67	20	13	69	177	433
Ethnicity: Hispanic	70	69	33	27	3	44	175	421
Ethnicity: Other/Unknown	4	8	13	0	3	9	11	48
Sex: Male	851	808	701	459	245	1010	2694	6768
Sex: Female	403	344	346	199	95	553	571	2511
Transmission category: Homosexual	517	508	410	219	137	605	2108	4504
Transmission category: Heterosexual	546	455	468	271	139	771	795	3445
Transmission category: Injection drug use	57	59	53	73	35	62	155	494
Transmission category: Inj. drug or sexual	43	29	29	27	14	31	74	247
Transmission category: Other/unknown	91	102	87	68	15	94	133	590



Summary statistics - data report Version 6.0
Situation 2024/H2

1.8 Table: Patients recruited in 2024, by HIV testing status

	BE	BS	GE	SG	TI	VD	ZH	total
Total	29	46	37	20	11	63	64	270
Diagnosis in 2024	8	19	6	5	6	22	30	96
Diagnosis before 2024	21	27	31	15	5	41	34	174
Days between diagnosis and registration, Median (IQR)	1869 [249, 4737]	773 [15, 2224]	1939 [370, 5652]	902 [184, 4004]	17 [10, 534]	1400 [26, 4247]	105 [14, 1428]	846 [25, 3751]
Documented negative test before 2024	14	26	17	7	5	17	32	118
No documented negative test before 2024	15	20	20	13	6	46	32	152

2.1 Table: CDC stages at recruitment and year (number of patients and median CD4 value)

	A				B				C				Total
	<200	200-500	>500	Median	<200	200-500	>500	Median	<200	200-500	>500	Median	
2019	27	104	147	523	11	6	5	215	26	15	7	186	348
2020	10	68	110	543	2	2	4	506	14	10	2	191	222
2021	14	76	143	579	4	2	2	207	11	10	3	204	265
2022	15	68	110	566	7	6	5	340	24	6	5	156	246
2023	18	77	108	517	4	2	4	330	8	7	8	271	236
2024	12	68	140	599	7	1	1	102	17	7	8	177	261

2.2 Table: CDC stages in active participants and year (number of patients and median CD4 value) *

	A				B				C				Total
	<200	200-500	>500	Median	<200	200-500	>500	Median	<200	200-500	>500	Median	
2019	87	1084	4589	705	48	514	1477	660	122	719	1249	574	9889
2020	66	1003	4600	715	42	461	1461	676	110	668	1259	580	9670
2021	66	1082	4604	704	38	460	1436	676	98	662	1235	584	9681
2022	67	994	4581	732	39	410	1366	690	99	615	1232	598	9403
2023	57	1012	4520	713	31	424	1323	680	69	590	1206	603	9232
2024	45	936	4657	740	28	371	1340	690	86	547	1226	618	9236

* At the first CD4 assessment of the year

2.3 Table: Most frequent AIDS defining events, number of diagnoses per year

	ESO	KSA	NHL	PCP	BPN	CMV	total AIDS cases
2019	14	12	8	11	4	8	109
2020	8	2	6	7	6	6	80
2021	7	2	6	11	4	3	65
2022	13	6	4	9	5	7	70
2023	6	3	5	7	5	3	47
2024	7	7	6	9	7	4	55

PCP = Pneumocystis pneumonia

ESO = oesophageal candidiasis

KSA = Kaposi sarcoma

NHL = Non-Hodgkin's lymphoma

BPN=Bacterial pneumonia

CMV = Cytomegalovirus disease

2.4 Table: Deaths during recent years, by CDC stage

	Stage A	Stage B	Stage C	Total	Patients seen
2019	22	19	18	59	9790
2020	17	13	37	67	9615
2021	27	18	44	89	9605
2022	20	19	28	67	9483
2023	26	16	22	64	9318
2024	32	16	21	69	9280

*Stage C indicates that the patients was at some point in stage C, not necessarily in the year of death: hierarchical category: stage C > stage B > stage A

2.5 Table: Reason of death

	HIV-related	Accident	Narcotics	Suicide	Other/Unknown	Total
2019	0	3	2	3	51	59
2020	2	1	2	4	58	67
2021	3	0	4	6	76	89
2022	0	1	0	4	63	67
2023	2	2	2	6	52	64
2024	1	1	1	5	63	71

*A detailed analysis on causes of death in the Swiss HIV Cohort Study was performed and recently published: Weber et al, Time Trends in Causes of Death in People with HIV: Insights from the Swiss HIV Cohort Study. Clin Infect Dis. 2024 Jan 12;ciae014. doi: 10.1093/cid/ciae014

3) Treatment status of all participants under follow-up

3.1 Table: Treatment status of participants under follow-up, by CD4 and year *

	Treatment naive				On treatment				Treatment interrupted				Total
	<200	200-349	350-500	>500	<200	200-349	350-500	>500	<200	200-349	350-500	>500	
2019	58	51	39	113	157	682	1459	7103	21	16	15	56	9770
2020	19	31	28	70	180	662	1353	7172	14	9	9	44	9591
2021	25	34	40	84	156	656	1411	7134	13	6	13	20	9592
2022	35	33	30	65	154	579	1359	7168	11	7	7	16	9464
2023	27	30	33	68	126	620	1334	7020	4	6	5	24	9297
2024	26	28	25	73	127	508	1254	7184	8	10	9	10	9262

*at first CD4 value

3.2 Table: Treatment status of participants under follow-up, by HIV viral load and year *

	Treatment naive (copies/ml)				On treatment (copies/ml)				Treatment interrupted (copies/ml)				Total
	0 - 50	51 - 400	401 - 100000	>100000	0 - 50	51 - 400	401 - 100000	>100000	0 - 50	51 - 400	401 - 100000	>100000	
2019	46	14	108	94	9053	234	99	11	42	11	40	13	9765
2020	36	9	54	51	9019	270	73	13	28	9	25	14	9601
2021	50	15	70	50	8976	289	83	5	25	2	13	13	9591
2022	33	12	61	56	8837	342	72	12	12	4	16	9	9466
2023	35	13	61	50	8655	353	75	12	18	3	9	9	9293
2024	40	14	44	53	8739	256	77	5	8	5	16	8	9265

*at first viral load in the reporting year

3.3 Table: Participants on ART by first, second and other regimen, median of the duration (days)

Treatment status	on first regimen		on second regimen		on third regimen		on fourth regimen		on fifth regimen		on ≥ sixth regimen		Total
	nb	median	nb	median	nb	median	nb	median	nb	median	nb	median	
2019	913	1087	1349	829	1343	752	1060	734	919	763	3834	716.5	9418
2020	856	1022	1277	908	1285	785	1104	716	906	799	3959	722	9387
2021	740	1212	1219	1096	1292	869	1185	792	908	840	3966	723	9310
2022	707	1120	1147	1142	1267	941	1201	906	947	899	3981	853	9250
2023	603	1133	1117	1143	1244	1066.5	1189	1081	931	1076	4012	1053.5	9096
2024	610	1121	1066	1199	1267	1201	1170	1251	961	1156	3998	1223.5	9072

3.4 The most frequent combinations: reference January 1st, 2025

REGIMEN	nb	%
BIC ETC TAF	2810	30
3TC DTG	2005	21
ETC RPV TAF	738	8
CABI RPV	452	5
DTG ETC TAF	392	4
COB ETC EVG TAF	360	4
3TC ABC DTG	351	4
3TC DOR TDF	261	3
ETC NVP TAF	177	2
3TC NVP	143	2
TOTAL	83	

3.5 Most frequent NRTI combinations: reference 1st January 2025

REGIMEN	nb	%
ETC TAF	5199	55
3TC	2254	24
3TC ABC	465	5
3TC TDF	278	3
ETC TDF	252	3
TOTAL	90	

3.5.1 Most frequent NRTI combinations: reference 1st July, 2024

REGIMEN	nb	%
ETC TAF	5212	56
3TC	2136	23
ABC 3TC	569	6
3TC TDF	269	3
ETC TDF	265	3
TOTAL	91	

3.5.2 Most frequent NRTI combinations: reference 1st January 2024

REGIMEN	nb	%
ETC TAF	5296	56
3TC	2027	22
3TC ABC	675	7
ETC TDF	269	3
3TC TDF	253	3
TOTAL	91	

3.5.3 Most frequent NRTI combinations: reference 1st January, 2023

REGIMEN	nb	%
ETC TAF	5491	58
3TC	1760	19
ABC 3TC	937	10
ETC TDF	343	4
3TC TDF	205	2
TOTAL	93	

3.6 Number of different substances: Median number of substances, and nr of patients taking 1, 2, 3, 4, 5, >5 substances

	median	1	2	3	4	5	>5
2018	3 [3,4]	106	335	6578	2398	334	68
2019	3 [3,3]	101	592	6755	1997	323	63
2020	3 [3,3]	83	912	6576	1674	322	62
2021	3 [3,3]	83	1437	6284	1335	293	51
2022	3 [3,3]	125	2084	5894	1033	267	45
2023	3 [2,3]	148	2499	5593	851	250	44
2024	3 [2,3]	169	2790	5408	726	237	41

3.7 Profile of participants on the four most frequent regimens in 2024

	BIC ETC TAF	3TC DTG	ETC RPV TAF	CABI RPV	others
TOTAL	2810	2005	738	452	3322
Age, Median (IQR)	56 (46,62)	54 (45,61)	56 (47,62)	47 (39,55.25)	57 (48,63)
Age: 18 to 24	57.4%	18.5%	0%	9.3%	14.8%
Age: 25 to 44	31.2%	23.3%	6.7%	9.2%	29.7%
Age: 45 to 64	29.6%	21.8%	8.4%	4.3%	35.9%
Age: >65	29.8%	18.5%	8%	1.4%	42.3%
Ethnicity: White	29.7%	22.1%	7.7%	4.2%	36.3%
Ethnicity: Black	29.6%	17.4%	9%	6.5%	37.6%
Ethnicity: Asian	35.5%	23%	7.8%	5%	28.7%
Ethnicity: Hispanic	32.8%	24%	8.6%	7.5%	27.1%
Ethnicity: Other/Unknown	40.8%	16.3%	4.1%	18.4%	20.4%
Sex: Male	31.4%	22.7%	7.8%	5.1%	33%
Sex: Female	26.7%	18.3%	8.2%	4.2%	42.7%
Transmission: Homosexual	30.8%	23%	8.4%	5.7%	32.1%
Transmission: Heterosexual	29%	21%	8.1%	4%	37.8%
Transmission: Injection drug use	31.6%	13.4%	5.9%	3.1%	46.1%
Transmission: Other/unknown	29.8%	23.3%	5.4%	5.2%	36.3%
Center 1*	19.4%	18%	12.3%	7.9%	42.4%
Center 2	35.6%	14.2%	10.1%	7.1%	32.9%
Center 3	26.8%	24.7%	6.5%	4.7%	37.3%
Center 4	29.7%	26.4%	5.5%	2.8%	35.6%
Center 5	35%	19.4%	7.8%	4%	33.6%
Center 6	26.1%	32.9%	3%	6.8%	31.2%
Center 7	19.2%	34.2%	5.2%	1.7%	39.7%

*The centers are scrambled separately in each table, e.g., Center 1 in table 3.7. is most likely not the same as Center 1 in table 3.7.1

3.7.1 Profile of participants on a Doravirine-containing regimen in 2024

	3TC DOR TDF	other DOR-containing	not DOR-containing
TOTAL	261	290	8776
Age, Median (IQR)	49 (42,57)	60.5 (55,65)	55 (46,62)
Age: 18 to 24	1.9%	0%	98.1%
Age: 25 to 44	4.5%	1.3%	94.2%
Age: 45 to 64	2.7%	3.2%	94.1%
Age: >65	1.2%	4.9%	93.9%
Ethnicity: White	2.5%	3.2%	94.3%
Ethnicity: Black	4.4%	3.5%	92.1%
Ethnicity: Asian	2.4%	1.9%	95.7%
Ethnicity: Hispanic	3.2%	1.6%	95.2%
Ethnicity: Other/Unknown	2%	0%	98%
Sex: Male	2.3%	3%	94.6%
Sex: Female	4%	3.3%	92.7%
Transmission: Homosexual	2.5%	2.9%	94.7%
Transmission: Heterosexual	3.4%	2.9%	93.6%
Transmission: Injection drug use	1.3%	5.5%	93.2%
Transmission: Other/unknown	3.4%	3.2%	93.5%
Center 1*	3.8%	6.4%	89.8%
Center 2	2.8%	1.7%	95.5%
Center 3	3%	1.7%	95.3%
Center 4	3.8%	1.7%	94.6%
Center 5	0.6%	0.9%	98.5%
Center 6	2.3%	3.8%	93.9%
Center 7	1.8%	0.9%	97.2%

*The centers are scrambled separately in each table, e.g., Center 1 in table 3.7. is most likely not the same as Center 1 in table 3.7.1

4) Treatment status at recruitment, and newly started ART regimen

4.1 Table: Treatment status at recruitment, by CD4 and year

	Treatment naive				On treatment				Treatment interrupted				Total
	<200	200-349	350-500	>500	<200	200-349	350-500	>500	<200	200-349	350-500	>500	
2019	50	46	35	72	13	18	22	82	1	2	1	6	348
2020	13	25	20	31	10	13	20	77	3	1	1	8	222
2021	23	28	31	53	5	14	13	88	1	2	0	7	265
2022	37	29	25	30	7	13	12	81	2	0	0	10	246
2023	21	29	22	46	9	9	24	72	0	0	2	2	236
2024	23	24	17	44	13	13	18	91	0	3	1	14	261

4.2 Table: Treatment status at recruitment, by HIV viral load and year

	Treatment naive (copies/ml)				On treatment (copies/ml)				Treatment interrupted (copies/ml)				Total
	0 - 50	51 - 400	401 - 100000	>100000	0 - 50	51 - 400	401 - 100000	>100000	0 - 50	51 - 400	401 - 100000	>100000	
2019	34	15	86	67	116	12	6	2	8	2	1	0	349
2020	15	4	35	40	113	7	6	3	6	1	1	0	231
2021	35	11	59	34	106	13	2	1	6	1	3	1	272
2022	17	15	46	41	106	6	3	1	9	1	0	1	246
2023	30	16	39	34	100	7	3	1	7	0	0	0	237
2024	26	11	31	40	126	8	6	2	8	2	0	0	260

4.3 The most frequent initial regimens started in 2024

REGIMEN	nb	%
BIC ETC TAF	87	72
3TC DTG	8	7
3TC DOR TDF	5	4
DTG ETC TAF	5	4
DTG ETC TDF	4	3
COB DRV DTG ETC TAF	3	2
Total	92	

4.3.1 The most frequent initial regimens started in 2023

REGIMEN	nb	%
BIC ETC TAF	96	78
DTG ETC TAF	8	7
3TC DOR TDF	3	2
COB DRV DTG ETC TAF	3	2
DTG ETC TDF	3	2
3TC DTG	2	2
Total	93	

4.3.2 The most frequent initial regimens started in 2022

REGIMEN	nb	%
BIC ETC TAF	102	73
DTG ETC TAF	7	5
3TC DTG	6	4
COB DRV DTG ETC TAF	6	4
3TC ABC DTG	3	2
DTG ETC TDF	3	2
Total	90	

4.4 Profile of participants starting ART in 2024

	BIC ETC TAF	not BIC ETC TAF
TOTAL	87	33
Age, Median (IQR)	40 (33,52)	39 (33,51)
Age: 18 to 24	77.8%	22.2%
Age: 25 to 44	66.2%	33.8%
Age: 45 to 64	81.6%	18.4%
Age: >65	75%	25%
Ethnicity: White	78.5%	21.5%
Ethnicity: Black	62.5%	37.5%
Ethnicity: Asian	75%	25%
Ethnicity: Hispanic	50%	50%
Ethnicity: Other/Unknown		
Sex: Male	77.9%	22.1%
Sex: Female	52%	48%
Transmission: Homosexual	69%	31%
Transmission: Heterosexual	73.9%	26.1%
Transmission: Injection drug use		
Transmission: Other/unknown	81.2%	18.8%
Center 1*	93.3%	6.7%
Center 2	61.9%	38.1%
Center 3	45.5%	54.5%
Center 4	88.9%	11.1%
Center 5	71.4%	28.6%
Center 6	71.4%	28.6%
Center 7	65.7%	34.3%

*The centers are scrambled separately in each table, e.g., Center 1 in table 3.7. is most likely not the same as Center 1 in table 4.4

5) Treatment switches and discontinuation

5.1 Table: The five most frequently discontinued regimens in 2024, by reason, number and fraction of all regimen prescribed

		Availability of optimized treatment	Avoiding/feeling long-term toxicity	Drug-drug interaction	CVD risk factors	Weight gain	Clinical trial start	Low-level vireamia/failure	Neurology	Kidney	Other	No. of disc. regimen*
2024	BIC ETC TAF	1.8% (51)	0.5% (15)	0.1% (4)	0% (1)	0.7% (20)	0.2% (6)	0% (1)	0.2% (7)	0.1% (4)	1.2% (35)	5.6% (156)
2024	3TC ABC DTG	15.7% (55)	10.3% (36)	0.3% (1)	6.8% (24)	0% (0)	0% (0)	0.3% (1)	0.6% (2)	0.6% (2)	6.6% (23)	41.6% (146)
2024	COB ETC EVG TAF	5.6% (20)	3.3% (12)	2.8% (10)	3.1% (11)	0% (0)	0% (0)	0.3% (1)	0.3% (1)	0.8% (3)	3.3% (12)	19.4% (70)
2024	DTG ETC TAF	11% (43)	0% (0)	0% (0)	0.5% (2)	0.3% (1)	1% (4)	0.5% (2)	0.3% (1)	0% (0)	2.3% (9)	16.3% (64)
2024	3TC DTG	0.7% (14)	0% (0)	0% (0)	0% (0)	0.2% (4)	0.3% (6)	0.2% (5)	0.4% (8)	0% (0)	0.9% (18)	2.7% (55)

*one regimen can have several reason for discontinuation

*the patients identity cannot be identified

5.1.1 Table: Reasons for switching to Doravirine-containing regimen in 2024

		Availability of optimized treatment	Avoiding/feeling long-term toxicity	Drug-drug interaction	CVD risk factors	Weight gain	Clinical trial start	Low-level vireamia/failure	Neurology	Kidney	Other	No. of switches to DOR
2024	to 3TC DOR TDF	2.3% (6)	1.1% (3)	0.8% (2)	0.4% (1)	6.5% (17)	0% (0)	0% (0)	2.7% (7)	0.4% (1)	2.7% (7)	17.2% (45)
2024	to other DOR-cont.	4.5% (13)	0.7% (2)	1% (3)	2.1% (6)	0.3% (1)	3.1% (9)	1.7% (5)	0.3% (1)	0% (0)	3.8% (11)	19.3% (56)



5.2.1 The most frequent treatment switches in 2024

REGIMEN	nb	%
3TC DTG	278	27
BIC ETC TAF	269	26
CABI RPV	91	9
3TC DOR TDF	53	5
DTG ETC TAF	24	2
Total	69	

5.2.1 The most frequent treatment switches in 2023

REGIMEN	nb	%
3TC DTG	352	27
BIC ETC TAF	334	25
CABI RPV	167	13
3TC DOR TDF	64	5
DTG ETC TAF	36	3
Total	73	

5.2.2 The most frequent treatment switches in 2022

REGIMEN	nb	%
3TC DTG	521	31
BIC ETC TAF	391	23
CABI RPV	198	12
3TC DOR TDF	66	4
3TC ABC DTG	40	2
DTG ETC TAF	40	2
Total	74	

5.3 The most frequent treatment switches in 2024: From -> To

REGIMEN	nb	%	Time until switch (days)
3TC ABC DTG -> 3TC DTG	102	11	2596.5
BIC ETC TAF -> 3TC DTG	50	6	1048
COB ETC EVG TAF -> BIC ETC TAF	40	4	2533.5
DTG ETC TAF -> BIC ETC TAF	35	4	2024
BIC ETC TAF -> CABI RPV	32	4	1152
3TC ABC DTG -> BIC ETC TAF	24	3	2807.5
BIC ETC TAF -> 3TC DOR TDF	20	2	682.5
Total	30		

5.3.1 Switches to Doravirine-containing regimen in 2024: From -> To

REGIMEN	nb	%	Time until switch (days)
INSTI -> DOR-containing	84	83.1	1110.5
PI -> DOR-containing	6	5.9	822.5
NNRTI -> DOR-containing	11	10.9	1891
Total	101	100	

5.3.2 Switches to Lenacapavir-containing regimen in 2024: From -> To

REGIMEN	nb	%	Time until switch (days)
different regimen*	3		
Total	na		

*More details will be provided once the sample size is higher

5.4 The most frequent treatment switches *after the first ART regimen* in 2024: From -> To

REGIMEN	nb	%	Time until switch
BIC ETC TAF -> 3TC DTG	21	16	796
3TC ABC DTG -> 3TC DTG	17	13	2719
BIC ETC TAF -> 3TC DOR TDF	11	9	309
BIC ETC TAF -> CABI RPV	11	9	1085
EFV ETC TDF -> 3TC DTG	5	4	4538
Total	23		

5.5 Profile of participants switching, most frequent switches in 2024

	3TC ABC DTG to 3TC DTG	BIC ETC TAF to 3TC DTG	COB ETC EVG TAF to BIC ETC TAF	Others
TOTAL	102	50	40	717
Age, Median (IQR)	53 (45.25,61.75)	49 (41,60.75)	57 (50.25,61.25)	53 (44,61)
Age: 18 to 24	0%	10%	0%	90%
Age: 25 to 44	11%	7%	3.1%	78.9%
Age: 45 to 64	12.3%	4.6%	4.8%	78.2%
Age: >65	8.8%	6.1%	5.4%	79.6%
Ethnicity: White	11.8%	5.9%	4.6%	77.7%
Ethnicity: Black	9.2%	2.7%	4.3%	83.8%
Ethnicity: Asian	12.2%	12.2%	7.3%	68.3%
Ethnicity: Hispanic	12.2%	4.9%	0%	82.9%
Ethnicity: Other/Unknown	14.3%	14.3%	0%	71.4%
Sex: Male	11.2%	5.9%	5.1%	77.7%
Sex: Female	11.5%	4.7%	2.9%	81%
Transmission category: Homosexual	10.7%	5.6%	5.8%	77.9%
Transmission category: Heterosexual	11.5%	4.8%	2.5%	81.2%
Transmission category: Injection drug use	12.1%	4.5%	6.1%	77.3%
Transmission category: Other/unknown	12.9%	10%	4.3%	72.9%
Center 1*	7.7%	4.2%	2.8%	85.2%
Center 2	18.4%	4%	1.6%	76%
Center 3	18%	6.8%	2.5%	72.7%
Center 4	3.2%	6.4%	9.3%	81.1%
Center 5	23.8%	4.8%	3.2%	68.3%
Center 6	14.3%	1.3%	2.6%	81.8%
Center 7	7.4%	11.1%	0%	81.5%

*The centers are scrambled separately in each table, e.g., Center 1 in table 5.5 is most likely not the same as Center 1 in table 5.5.1

5.5.1 Profile of participants switching to BIC ETC TAF 2024

	COB ETC EVG TAF to BIC ETC TAF	DTG ETC TAF to BIC ETC TAF	ETC RPV TAF to BIC ETC TAF	OTHERS SWITCHES
TOTAL	40	35	24	24
Age, Median (IQR)	57 (50.25,61.25)	60 (47,63.5)	49 (44.5,57.5)	49 (44.5,57.5)
Age: 18 to 24	0%	0%	0%	0%
Age: 25 to 44	3.1%	3.5%	2.6%	2.6%
Age: 45 to 64	4.8%	3.5%	3.3%	3.3%
Age: >65	5.4%	6.1%	0%	0%
Ethnicity: White	4.6%	3.5%	1.9%	1.9%
Ethnicity: Black	4.3%	4.3%	3.8%	3.8%
Ethnicity: Asian	7.3%	2.4%	4.9%	4.9%
Ethnicity: Hispanic	0%	9.8%	4.9%	4.9%
Ethnicity: Other/Unknown	0%	0%	0%	0%
Sex: Male	5.1%	3.5%	2.6%	2.6%
Sex: Female	2.9%	4.7%	2.5%	2.5%
Transmission category: Homosexual	5.8%	2.9%	1.9%	1.9%
Transmission category: Heterosexual	2.5%	4.2%	3.1%	3.1%
Transmission category: Injection drug use	6.1%	6.1%	4.5%	4.5%
Transmission category: Other/unknown	4.3%	5.7%	1.4%	1.4%
Center 1*	3.2%	3.2%	1.6%	1.6%
Center 2	0%	3.7%	3.7%	3.7%
Center 3	2.8%	2.8%	2.8%	2.8%
Center 4	2.6%	3.9%	0%	0%
Center 5	1.6%	6.4%	3.2%	3.2%
Center 6	2.5%	1.9%	3.7%	3.7%
Center 7	9.3%	4.6%	2.1%	2.1%

*The centers are scrambled separately in each table, e.g., Center 1 in table 3.7. is most likely not the same as Center 1 in table 3.7.1

5.5.2 Profile of participants switching to Doravirine-containing treatment in 2024

	Switching to 3TC DOR TDF	Switching to BIC DOR ETC TAF	Switching to other DOR-cont.	Switching to non- DOR cont.
TOTAL	44	18	38	751
Age, Median (IQR)	47.5 (38.5,50.25)	59 (54.25,64)	59 (52,64)	53 (44,61)
Age: 18 to 24	0%	0%	0%	100%
Age: 25 to 44	7.5%	0.9%	1.9%	89.7%
Age: 45 to 64	5.1%	2.4%	5.1%	87.4%
Age: >65	2.3%	3%	6.8%	88%
Ethnicity: White	5.1%	1.9%	5.1%	88%
Ethnicity: Black	4.7%	2.9%	4.7%	87.6%
Ethnicity: Asian	7.5%	5%	0%	87.5%
Ethnicity: Hispanic	5.1%	0%	0%	94.9%
Ethnicity: Other/Unknown	16.7%	0%	0%	83.3%
Sex: Male	4.9%	2%	4.2%	88.8%
Sex: Female	5.9%	2.4%	5.1%	86.7%
Transmission category: Homosexual	5.9%	1.8%	3.1%	89.2%
Transmission category: Heterosexual	4.6%	1.5%	5.5%	88.4%
Transmission category: Injection drug use	0%	4.8%	8.1%	87.1%
Transmission category: Other/unknown	9.1%	4.5%	4.5%	81.8%
Center 1*	4.9%	3.4%	6.4%	85.3%
Center 2	5.3%	2.6%	0%	92.1%
Center 3	4.3%	1.7%	2.6%	91.4%
Center 4	3.9%	0%	1.3%	94.7%
Center 5	9.5%	2.4%	7.9%	80.2%
Center 6	0%	0%	3.2%	96.8%
Center 7	6.1%	0%	10.2%	83.7%

*The centers are scrambled separately in each table, e.g., Center 1 in table 5.5. is most likely not the same as Center 1 in table 5.5.2



5.5.3 Profile of participants switching to Lenacapavir-containing treatment in 2024*

Total	3
-------	---

**Full patient characteristics will be provided once a certain sample size is reached to avoid identification of individual patients.*

6.1 Table: Status of HBV infection of participants under follow-up having a HBV screening result, by reference date*

	No HBV infection (AntiHBc negativ)	HBV infection (AntiHBc positive)	missing AntiHBc	Total
2019	5460 (55.8%)	3785 (38.7%)	545 (5.6%)	9790 (100%)
2020	5420 (56.4%)	3674 (38.2%)	521 (5.4%)	9615 (100%)
2021	5440 (56.6%)	3591 (37.4%)	574 (6%)	9605 (100%)
2022	5411 (57.1%)	3488 (36.8%)	584 (6.2%)	9483 (100%)
2023	5484 (58.9%)	3396 (36.4%)	438 (4.7%)	9318 (100%)
2024	5536 (59.7%)	3321 (35.8%)	423 (4.6%)	9280 (100%)

*Under follow-up means a documented follow-up visit in the reference year

6.2 Table: HBV infection by centre

	BE	BS	GE	SG	TI	VD	ZH	Total
2019	520	463	567	246	129	625	1246	3796
2020	508	447	538	248	122	619	1192	3674
2021	505	434	510	246	120	610	1166	3591
2022	478	423	491	235	115	608	1138	3488
2023	464	407	452	235	120	594	1124	3396
2024	434	394	468	234	117	584	1090	3321

7.1 Table: Status of HCV infection: participants with an anti-HCV screening result, under follow-up at the reference date

	HCV Ab negative	HCV Ab positive			Unknown HCV Ab	Total
		replicating	not replicating	unknown replication		
2019	8117	214	1310	53	96	9790
2020	8046	189	1274	40	66	9615
2021	8051	181	1255	35	83	9605
2022	7996	65	1301	17	104	9483
2023	7968	50	1216	16	68	9318
2024	7984	46	1164	18	68	9280

7.2 Table: The most frequent HCV genotypes among participants with a replicating HCV infection, under follow-up

	1	2	3	4	other	unknown	total
2019	85	2	28	39	0	60	214
2020	64	2	26	32	0	65	189
2021	66	2	21	27	0	65	181
2022	21	0	8	11	0	25	65
2023	12	0	7	8	0	23	50
2024	11	0	6	10	0	19	46

7.3 Table: HCV treatment status of participants, under follow-up at the reference date*

	Treatment ongoing	Treatment terminated
2019	2	51
2020	5	22
2021	0	18
2022	1	5
2023	2	11
2024	0	6

**Update made for all years, due to additional data available*